Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2012
At a glance
- Drugs Imatinib (Primary) ; Panobinostat (Primary)
- Indications Sarcoma
- Focus Adverse reactions
- 26 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Feb 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 03 Oct 2011 Additional lead trial investigators (Scott Schuetze, Edwin Choy) identified as reported by ClinicalTrials.gov.